Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: The experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008)

Haemophilia

Volumn 18, Issue 6, 2012, Pages 990-996

  Young, G ^a   Cooper, D L ^b   Gut, R Z ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NOVO NORDISK INC   (United States)

Author keywords

Haemophilia; Haemostasis; Inhibitors; Recombinant FVIIa; Registry; Retrospective

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ARTICLE; BLEEDING; CHILD; DRUG EFFICACY; FEMALE; HEMARTHROSIS; HEMOPHILIA; HUMAN; INFANT; JOINT; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MEDICAL SOCIETY; MUCOSAL BLEEDING; MULTICENTER STUDY; MUSCLE; MUSCLE BLEEDING; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUBCUTANEOUS BLEEDING; THROMBOSIS;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIIA; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; INFANT; INFANT, NEWBORN; MALE; RECOMBINANT PROTEINS; REGISTRIES; RESEARCH; SOCIETIES, SCIENTIFIC; YOUNG ADULT;

EID: 84868214110     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02864.x     Document Type: Article

References (15)

1. Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost 2006; 32(Suppl. 1): 77-85.
2. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998; 9: 119-28.
3. Lusher JM, Roberts HR, Davignon G et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998; 4: 790-8.
4. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
5. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287-94.
6. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 2003; 1: 450-5.
7. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71.
8. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95: 600-5.
9. NovoSeven RT [package insert]. Bagsvaerd, Denmark: Novo Nordisk A/S, 2010.
10. European Medicines Agency. NovoSeven (Eptacog Alfa) EPAR Summary for the Public. Doc. Ref.: EMEA/264577/2009. EMEA/H/C/74. London, UK: European Medicines Agency, 2009.
11. Nazzaro AM, Owens S, Hoots WK, Larson KL. Knowledge, attitudes, and behaviors of youths in the US hemophilia population: results of a national survey. Am J Public Health 2006; 96: 1618-22.
12. Salaj P, Brabec P, Penka M et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009; 15: 752-9.
13. Kavakli K, Yesilipek A, Antmen B et al. The value of early treatment in patients with haemophilia and inhibitors. Haemophilia 2010; 16: 487-94.
14. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
15. Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl 1998; 63: 7-10.